FDA Permits Marketing of App to Help Treat Substance Abuse

Share this content:
FDA Permits Marketing of App to Help Treat Substance Abuse
FDA Permits Marketing of App to Help Treat Substance Abuse

THURSDAY, Sept. 14, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has permitted marketing of the first mobile app to help treat substance use disorders, the agency said Thursday in a news release.

The Reset application is designed to help treat abuse of alcohol, cocaine, marijuana, and stimulant medications. But the app is not intended for opioid dependence, the FDA said.

The newly-approved app delivers behavioral therapy that's designed to "increase abstinence from substance abuse and increase retention in outpatient therapy programs," the FDA said.

The agency reviewed a 12-week clinical study involving 399 patients. Among those who used the app, 40.3 percent abstained from further alcohol, cocaine, marijuana, or stimulant use, compared with 17.6 percent among those who did not use the app.

Approval of the app was given to Pear Therapeutics, based in Boston and San Francisco.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ACG: Diphenhydramine Ups Sedation in Chronic Opioid Users

ACG: Diphenhydramine Ups Sedation in Chronic Opioid Users

Improvement in sedation scores for patients using chronic opioids scheduled to undergo colonoscopy

Online Ratings Not Aligned With Objective Quality Measures

Online Ratings Not Aligned With Objective Quality Measures

In addition, consumer ratings are consistent across platforms for specialist physicians

Most Female Physicians Have Faced Sexist Patient Comments

Most Female Physicians Have Faced Sexist Patient Comments

Sexual harassment by patients can negatively affect physician-patient relationship, quality of care

is free, fast, and customized just for you!

Already a member?

Sign In Now »